Novavax approved as fourth COVID-19 vaccine
August 8, 2022
This article is for all providers caring for our members
The Centers for Disease Control and Prevention (CDC) recently issued emergency use authorization (EUA) for the Novavax COVID-19 vaccine, the fourth vaccine approved to reduce the risks of the novel coronavirus, including the risk of severe illness and death.
Novavax, the first protein-based vaccine, is authorized for use in adults 18 and older who have not previously been vaccinated against COVID-19.
Novavax joins the roster of safe, effective vaccines that includes Moderna, Pfizer, and Johnson & Johnson. All four are covered by health plans, including Blue Cross Blue Shield of Massachusetts, with no out-of-pocket cost.
Dosage
The CDC recommends that:
- people receiving a first dose of the Novavax vaccine get a second dose three weeks after the first dose. Novavax is not authorized for use as a booster dose at this time.
- the Novavax vaccine only be given to individuals who have not previously received any other COVID-19 vaccine.
Coverage for our members
- As is currently the case with other COVID-19 vaccines, Blue Cross Blue Shield of Massachusetts will cover the cost of the administration of the Novavax COVID-19 vaccine in full. The federal government is covering the cost of the vaccine itself.
- Our members should not be charged a copayment or co-insurance for the vaccine.
- Copayments, deductible, and co-insurance may apply if other health care services are provided at the time the member is vaccinated.
For more information
- U.S. FDA: Novavax COVID-19 Vaccine, Adjuvanted
- Coverage article: What you need to know about the Novavax vaccine
MPC_030620-1N-232